Title : Procalcitonin as a predictor of mortality among patients admitted with pulmonary tuberculosis and community acquired pneumonia in a tertiary referral hospital for infectious disease
Pulmonary tuberculosis is a worldwide global health burden. According to the WHO guidelines on tuberculosis infection prevention and control that was updated last 2019, tuberculosis accounts for more than 10million cases per year and the deaths caused by Tuberculosis alone accounts to 42% between the year 2000 to 2017. Procalcitonin is a known systemic inflammatory calcitonin and studies have concluded that Procalcitonin is a useful biomarker for diagnosis of estimating the severity or even predicting mortality of Sepsis, hence regarded as a useful marker in these conditions but there are only limited studies involving pulmonary tuberculosis and procalcitonin. This study determined the role of Procalcitonin as a biomarker in predicting mortality among adult patients admitted as a case of Pulmonary Tuberculosis and Community Acquired Pneumonia in a Tertiary Referral Hospital for Infectious Disease in Manila.
Audience take away:
This study determines the relevance of an infectious biomarker, Procalcitonin in the severity of Pulmonary Tuberculosis. This will help physicians on how to approach all patients admitted with a diagnosis of Pulmonary Tuberculosis and community acquired pneumonia. Specific Objective of the study is to investigate the association between Procalcitonin level with the following: Hematologic parameters (leukocyte counts, hemoglobin and platelet); Blood chemistry parameters (BUN, creatinine, albumin, SGPT, SGOT, FBS, Total cholesterol); Presence of co-morbidities with the level of procalcitonin diagnosed with of Pulmonary Tuberculosis and Community Acquired Pneumonia; Social history specifically: patient’s smoking and alcohol intake history; Length of hospital stay ; Outcome; and Presence of bacterial isolate in the culture results.